Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 5, 2014, Pages 542-548

  Caudle, K E ^a   Rettie, A E ^b   Whirl Carrillo, M ^c   Smith, L H ^d   Mintzer, S ^e   Lee, M T ^f,g,h   Klein, T E ^c   Callaghan, J T ^d,i  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f RIKEN Center for Integrative Medical Sciences   (Japan)

^g INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FOSPHENYTOIN SODIUM; HLA B ANTIGEN; LEUKOCYTE ANTIGEN; PHENYTOIN; ANTICONVULSIVE AGENT;

ALLELE; COST EFFECTIVENESS ANALYSIS; DRUG USE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; INFORMATION; PHARMACOGENETICS; PRACTICE GUIDELINE; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; GENETICS; HUMAN; PHENOTYPE;

ANTICONVULSANTS; CYTOCHROME P-450 CYP2C9; GENOTYPE; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; PHENOTYPE; PHENYTOIN; PRACTICE GUIDELINES AS TOPIC;

EID: 84908220839     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.159     Document Type: Review

References (36)

1. Martin, M. A., Klein, T. E., Dong, B. J., Pirmohamed, M., Haas, D. W. & Kroetz, D. L.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91, 734-738 (2012).
2. Lee, C. R., Goldstein, J. A. & Pieper, J. A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263 (2002).
3. Hershfield, M. S. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93, 153-158 (2013).
4. Leckband, S. G. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94, 324-328 (2013).
5. Twardowschy, C. A., Werneck, L. C., Scola, R. H., Borgio, J. G., De Paola, L. & Silvado, C. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy. Seizure 22, 194-197 (2013).
6. Johnson, J. A. et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
7. Parker, W. A. & Shearer, C. A. Phenytoin hepatotoxicity: a case report and review. Neurology 29, 175-178 (1979).
8. Purkins, L., Wood, N., Ghahramani, P., Love, E. R., Eve, M. D. & Fielding, A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. 56 (suppl. 1), 37-44 (2003).
9. Hung, S. I. et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11, 349-356 (2010).
10. Cheung, Y. K., Cheng, S. H., Chan, E. J., Lo, S. V., Ng, M. H. & Kwan, P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54, 1307-1314 (2013).
11. Hung, C. C., Lin, C. J., Chen, C. C., Chang, C. J. & Liou, H. H. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 26, 534-540 (2004).
12. van der Weide, J., Steijns, L. S., van Weelden, M. J. & de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291 (2001).
13. Hung, C. C. et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics 13, 1339-1349 (2012).
14. Brandolese, R., Scordo, M. G., Spina, E., Gusella, M. & Padrini, R. Severe phenytoin intoxication in a subject homozygous for CYP2C9∗3. Clin. Pharmacol. Ther. 70, 391-394 (2001).
15. Dorado, P., Lopez-Torres, E., Peñas-Lledó, E. M., Martinez-Anton, J. & Llerena, A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 13, 359-361 (2013).
16. Hennessy, S. et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J. Clin. Pharmacol. 49, 1483-1487 (2009).
17. Ramasamy, K., Narayan, S. K., Chanolean, S. & Chandrasekaran, A. Severe phenytoin toxicity in a CYP2C9∗3∗3 homozygous mutant from India. Neurol. India 55, 408-409 (2007).
18. Rettie, A. E., Haining, R. L., Bajpai, M. & Levy, R. H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35, 253-255 (1999).
19. Aynacioglu, A. S. et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48, 409-415 (1999).
20. Kerb, R. et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1, 204-210 (2001).
21. Cresteil, T., Beaune, P., Kremers, P., Celier, C., Guengerich, F. P. & Leroux, J. P. Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes. Eur. J. Biochem. 151, 345-350 (1985).
22. Koukouritaki, S. B. et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308, 965-974 (2004).
23. Suzuki, Y., Mimaki, T., Cox, S., Koepke, J., Hayes, J. & Walson, P. D. Phenytoin age-dose-concentration relationship in children. Ther. Drug Monit. 16, 145-150 (1994).
24. Dorado, P., López-Torres, E., Peñas-Lledó, E. M., Martínez-Antón, J. & Llerena, A. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 13, 359-361 (2013).
25. Yip, V. L., Marson, A. G., Jorgensen, A. L., Pirmohamed, M. & Alfirevic, A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92, 757-765 (2012).
26. Mintzer, S. et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann. Neurol. 65, 448-456 (2009).
27. Thorn, C. F., Whirl-Carrillo, M., Leeder, J. S., Klein, T. E. & Altman, R. B. PharmGKB summary: phenytoin pathway. Pharmacogenet. Genomics 22, 466-470 (2012).
28. Shankarkumar, U., Shah, K. N. & Ghosh, K. Letter: HLA B 1502 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India. Epilepsia 50, 1837-1838 (2009).
29. Lin, L. C., Lai, P. C., Yang, S. F. & Yang, R. C. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J. Med. Sci. 25, 82-86 (2009).
30. Chen, Y. C., Chu, C. Y. & Hsiao, C. H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B 1502 genotype. J. Eur. Acad. Dermatol. Venereol. 23, 702-703 (2009).
31. Locharernkul, C. et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B 1502 allele in Thai population. Epilepsia 49, 2087-2091 (2008).
32. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417 (2012).
33. Hu, F. Y., Wu, X. T., An, D. M., Yan, B., Stefan, H. & Zhou, D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B 1502 allele in Chinese Han population. Seizure 20, 160-162 (2011).
34. Hu, F. Y., Wu, X. T., An, D. M., Yan, B., Stefan, H. & Zhou, D. Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B 1502 allele in mainland China: two cases. Seizure 20, 431-432 (2011).
35. Bochner, F., Hooper, W. D., Eadie, M. J. & Tyrer, J. H. Decreased capacity to metabolize diphenylhydantoin in a patient with hypersensitivity to warfarin. Aust. N. Z. J. Med. 5, 462-466 (1975).
36. Dong, D., Sung, C. & Finkelstein, E. A. Cost-effectiveness of HLA-B 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 79, 1259-1267 (2012).